DSCI is a great NASDAQ pick for the next couple of days: READ ON!
DSCI – Derma Sciences Inc.
Recent Price: 19/32
52-wk Low/High: $.25 / $2.22
Float: ~600k shares
Address: 214 Carnegie Center, Suite 100 Princeton, NJ 08540
Phone: (609) 514-4744 Fax: (609) 514-0502
Industry: Biotechnology
Officers: Edward J. Quilty, Chmn.
Richard S. Mink, COO
Charles F. Caudell III, Exec. VP
Stephen T. Wills, CFO
Investor Contact: Mark Alvino (212) 698-1360
The Company:
Derma Sciences, Inc. develops, markets, and sells topical, nutrient-based wound care products. The Company uses its proprietary zinc formulation for the treatment of skin ulcerations such as pressure and venous ulcers, surgical incisions, and burns. Derma, through a subsidiary, also manufactures wound closure products and specialty fasteners for catheters, tubes, and wound irrigation.
The company's mission is...To be a leading provider of a full line of technologically advanced skin and wound care products supported by exceptional customer service, education and clinical support
dermasciences.com
Reasons:
First of all, they have an AWESOME website that is easy to browse through and is perfectly designed to be an effective sales tool. Please take some time and browse through its contents; you won't be disappointed!
The company is in the end swing of a full turnaround. Derma Sciences was having some big troubles several years ago: They only had a single product (a zinc based wound care product), and had a hard time finding distribution channels. New management came in in 1997and since they have acquired two companies (Sunshine Products, Inc. and Genetic Laboratories Wound Care Inc.) which has expanded the product line to more than three wound based areas. And that's not all.
Management has been working to increase the distribution channels and recently signed on Omnicare Pharmacies, the nation's largest provider of pharmacy services to long-term care institutions. This major step in getting the products out on the market is valued at more than $1 million annually. In addition, over thirty sales representatives have been hired to increase the distribution channels.
In fact, Mr. Alvino stated that annual revenues have been increased from $4.5 million to $12 million. That's nearly 3-fold. The current price is well below BV and CV: Put simply: it's a steal at these rock-bottom prices.
If that isn't good enough, there are two big names behind DSCI: Gaylord Assoc. & Paramount/Aries. I don't know much about Paramount/Aries (read about it on SI), but according to Mr. Alvino, Gaylord is headed by Bill Grant, the ex-chairman of Bristol-Meyers.
In the short-term horizon: An earnings release due within the next week, of which Mark Alvino refused to comment about other than saying that it was going to look good. Also, the company has filed an appeal about delistment which won't be even heard until July. Most interestingly, the ONLY reason for delistment is NASDAQ's stupid and arbitrary $1 requirement.
Professional Affiliations:
National Association for the Support of Long Term Care
National Pressure Ulcer Advisory Panel
American Management Association
National Association for Home Care
Pennsylvania Bioprocessing Resource Center
Association for the Advancement of Wound Care
National Wound Care Coalition
The Wound Healing Society
More links & sources:
quote.yahoo.com
quote.bloomberg.com.
stockpoint.com |
